IRCT2013122811763N15 IRCT 2014-01-02 Vice chancellor for research, Isfahan University of Medical Sciences Effect of Symbiotic on Non-Alcoholic Fatty Liver Disease (NAFLD) Effects of Symbiotic on inflammatory markers, liver function, lipid profile, sonographic findings and body composition in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) 2014-01-10 anticipated 80 Complete https://irct.ir/trial/11925 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: This study will be a double blind clinical trial. The researcher and the patients will not know that each patient will be in which group, treatment or control. The supplements and placebo tablets will be coded as A and B in similar packets by a person that will be unaware from goals of the study. N/A NAFLD. Intervention 1: Daily oral consumption of Symbiotic supplement produced by Zist takhmir company with Familact commercial name contain 500 mg of seven Probiotic bacteria species and Fructooligosaccharides with below composition for two months: Lactobacillus Casei, Lactobacillus Acidopholus, Lactobacillus Rhamnosus, Lactobacillus Bulgaricus, Bifidobacterium Breve, Bifidobacterium Longum, Streptococcus Thermophiles and giving physical activity and dietary recommendation about NAFLD to patients at the baseline. Intervention 2: Daily Oral consumption of one tablet /day of placebo contain starch for two months and dietary recommendation about NAFLD to patients at the baseline.